Loading...
XTAI1733
Market cap92mUSD
Dec 25, Last price  
30.10TWD
1D
2.72%
1Q
2.20%
Jan 2017
-26.76%
Name

Apex Biotechnology Corp

Chart & Performance

D1W1MN
XTAI:1733 chart
P/E
25.98
P/S
1.79
EPS
1.16
Div Yield, %
4.65%
Shrs. gr., 5y
-2.19%
Rev. gr., 5y
-3.88%
Revenues
1.68b
-25.29%
1,438,917,0001,749,690,0001,876,273,0002,026,086,0001,829,221,0001,788,929,0001,847,454,0001,763,284,0001,795,300,0002,043,614,0002,198,862,0002,005,337,0002,131,656,0002,244,176,0001,676,537,000
Net income
116m
-36.31%
326,483,000453,949,000526,617,000522,710,000371,221,000273,377,000261,853,0003,181,00085,553,00095,119,000113,859,00094,795,000202,224,000181,785,000115,783,000
CFO
230m
+765.61%
391,286,000465,587,000273,447,000509,665,000484,767,000267,604,000472,152,000298,057,00070,828,00067,566,000462,523,000280,603,000179,868,00026,616,000230,391,000
Dividend
May 17, 20241.1 TWD/sh
Earnings
Apr 30, 2025

Profile

Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing, and hemoglobin screening systems. It also provides pesticide residues check systems; and care management and tele-health services. The company was founded in 1997 and is headquartered in Hsinchu City, Taiwan.
URL
https://www.apexbio.com.tw/
IPO date
Sep 17, 2001
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,676,537
-25.29%
2,244,176
5.28%
2,131,656
6.30%
Cost of revenue
1,533,004
2,067,616
1,930,202
Unusual Expense (Income)
NOPBT
143,533
176,560
201,454
NOPBT Margin
8.56%
7.87%
9.45%
Operating Taxes
25,248
18,124
(17,353)
Tax Rate
17.59%
10.27%
NOPAT
118,285
158,436
218,807
Net income
115,783
-36.31%
181,785
-10.11%
202,224
113.33%
Dividends
(139,930)
(129,935)
(109,315)
Dividend yield
3.46%
5.05%
3.98%
Proceeds from repurchase of equity
12,246
BB yield
-0.45%
Debt
Debt current
64,635
121,239
215,617
Long-term debt
239,592
253,350
262,206
Deferred revenue
Other long-term liabilities
477
485
479
Net debt
(84,019)
36,684
(153,426)
Cash flow
Cash from operating activities
230,391
26,616
179,868
CAPEX
(21,914)
(40,200)
(26,199)
Cash from investing activities
(22,497)
(41,366)
(35,017)
Cash from financing activities
(168,141)
(237,602)
(351,273)
FCF
183,668
(63,275)
121,307
Balance
Cash
443,914
397,534
631,249
Long term investments
(55,668)
(59,629)
Excess cash
304,419
225,696
524,666
Stockholders' equity
1,768,772
1,789,731
1,725,394
Invested Capital
1,673,823
1,799,674
1,532,531
ROIC
6.81%
9.51%
14.64%
ROCE
7.26%
8.70%
9.78%
EV
Common stock shares outstanding
100,326
100,671
105,637
Price
40.30
57.73%
25.55
-1.73%
26.00
9.70%
Market cap
4,043,138
57.19%
2,572,144
-6.35%
2,746,562
2.54%
EV
3,959,619
2,609,397
2,593,960
EBITDA
219,243
270,660
297,129
EV/EBITDA
18.06
9.64
8.73
Interest
4,388
5,398
12,530
Interest/NOPBT
3.06%
3.06%
6.22%